The bacterial second messenger cyclic diGMP exhibits potent adjuvant properties

被引：70

作者：

Ebensen, Thomas ^{[1
]}

Schulze, Kai ^{[1
]}

Riese, Peggy ^{[1
]}

Link, Claudia ^{[1
]}

Morr, Michael ^{[1
]}

Guzman, Carlos A. ^{[1
]}

机构：

[1] Helmholts Ctr Infect Res, Dept Vaccinol, D-38124 Braunschweig, Germany

来源：

VACCINE | 2007年 / 25卷 / 08期

关键词：

adjuvant; cdiGMP; immune modulator; vaccine;

D O I：

10.1016/j.vaccine.2006.10.033

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

The identification of new adjuvants is a critical need in vaccinology. In this work, it is demonstrated that bis-(3',5')-cyclic dimeric guanosine monophosphate (cdiGMP) exhibits potent adjuvant properties. Subcutaneous co-administration of cdiGMP with P-galactosidase (P-Gal) to mice resulted in the elicitation of significantly higher antigen-specific serum IgG titres than in animals receiving P-Gal alone. Strong cellular immune responses, which were characterized by a balanced Th1/Th2 pattern, were also observed in response to the P-Gal protein and a peptide encompassing its MHC class I-restricted epitope in immunized animals. These results suggest that cdiGMP represents a promising adjuvant for vaccine development. (c) 2006 Elsevier Ltd. All rights reserved.

引用

页码：1464 / 1469

页数：6

共 41 条

[1]

Bohjanen Kimberly A, 2004, Minn Med, V87, P34

[2] Efficient mucosal delivery of the HIV-1 Tat protein using the synthetic lipopeptide MALP-2 as adjuvant [J].

Borsutzky, S ;

Fiorelli, V ;

Ebensen, T ;

Tripiciano, A ;

Rharbaoui, F ;

Scoglio, A ;

Link, C ;

Nappi, F ;

Morr, M ;

Buttó, S ;

Cafaro, A ;

Mühlradt, PF ;

Ensoli, B ;

Guzmán, CA .

EUROPEAN JOURNAL OF IMMUNOLOGY, 2003, 33 (06) :1548-1556

[3] Efficient systemic and mucosal responses against the HIV-1 Tat protein by prime/boost vaccination using the lipopeptide MALP-2 as adjuvant [J].

Borsutzky, S ;

Ebensen, T ;

Link, C ;

Becker, PD ;

Fiorelli, V ;

Cafaro, A ;

Ensoli, B ;

Guzmán, CA .

VACCINE, 2006, 24 (12) :2049-2056

[4] Immunological foundations to the quest for new vaccine adjuvants [J].

Burdin, N ;

Guy, B ;

Moingeon, P .

BIODRUGS, 2004, 18 (02) :79-93

[5] An integrated approach of immunogenomics and bioinformatics to identify new Tumor Associated Antigens (TAA) for mammary cancer immunological prevention [J].

Cavallo, F ;

Astolfi, A ;

Iezzi, M ;

Cordero, F ;

Lollini, PL ;

Forni, G ;

Calogero, R .

BMC BIOINFORMATICS, 2005, 6 (Suppl 4)

[6] New approaches towards the identification of antibiotic and vaccine targets in Streptococcus pneumoniae [J].

Di Guilmi, AM ;

Dessen, A .

EMBO REPORTS, 2002, 3 (08) :728-734

[7]

Durrant L G, 2003, Expert Opin Emerg Drugs, V8, P489, DOI 10.1517/14728214.8.2.489

[8] Bacterial ghosts are an efficient delivery system for DNA vaccines [J].

Ebensen, T ;

Paukner, S ;

Link, C ;

Kudela, P ;

de Domenico, C ;

Lubitz, W ;

Guzmán, CA .

JOURNAL OF IMMUNOLOGY, 2004, 172 (11) :6858-6865

[9] New Adjuvants for parenteral and mucosal Vaccines [J].

Guy, B ;

Burdin, N .

THERAPIE, 2005, 60 (03) :235-241

[10] The VITAL assay: a versatile fluorometric technique for assessing CTL- and NKT-mediated cytotoxicity against multiple targets in vitro and in vivo [J].

Hermans, IF ;

Silk, JD ;

Yang, JP ;

Palmowski, MJ ;

Gileadi, U ;

McCarthy, C ;

Salio, M ;

Ronchese, F ;

Cerundolo, V .

JOURNAL OF IMMUNOLOGICAL METHODS, 2004, 285 (01) :25-40

← 1 2 3 4 5 →